ETF-Investor

VRTX Vertex Pharmaceuticals

$520.66-2.94%2026-11-19 · Quote reference; see timestamp

01Recent performance

PeriodReturnHistorical percentile
Daily-2.94%Insufficient history
WTD—Insufficient history
MTD—Insufficient history
Period comparison through 2026-11-19
YTD—
From 52W high—
IV30—

Loading full research…

02How expensive is the company?

TTM PE 33.50×

TTM PE 33.50× · 67.54%
0%25%50%75%100%

Actual history 14.72Y · 114 month-end samples · 2012-02-29 — 2026-10-30

A comparison with its own history, not a standalone investment decision.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
2012-02-292026-10-30

PB 6.31×

PB 6.31× · 15.00%
0%25%50%75%100%

Actual history 19.97Y · 240 month-end samples · 2006-11-30 — 2026-10-30

PB is affected by buybacks and equity structure; it is not a standalone trade signal.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
1997-01-312026-10-30

03Earnings outlook

Forward PE30.69×
Expected EPS growth—

Forward PE · Futu · 2026-11-01

No verified comparable EPS growth forecast. Growth is not inferred from valuation ratios.

No verified comparable Forward PE history; no percentile scale is shown.

04ETFs holding the company

Loading full research…

05Peers & similar companies

Peers and similar companies first, followed by common stocks where needed.

Watch
ABBV——Similar business————————
AMGN——Similar business————————
BIIB——Similar business————————
GILD——Similar business————————
JNJ——Similar business————————
LLY——Similar business————————
MRK——Similar business————————
PFE——Similar business————————
REGN——Similar business————————
UTHR——Similar business————————

Loading existing stock data…

Percentiles use each company’s own history; actual years appear beside values. Missing data is shown as —. Quote and valuation dates may differ; hover over values for available dates.

06Understand the company

The business in one sentence
Develops and sells treatments for serious diseases, including cystic fibrosis.

How it earns money
Earns most revenue from cystic fibrosis medicines and develops or commercializes other therapies, including collaborations.

Why customers choose it · Research perspective
Medicines target eligible genotypes; efficacy and long-term use support adoption. New areas need their own access channels.

What to watch next · Research perspective
Track cystic fibrosis sales, uptake outside the core and trial milestones to assess diversification.

Sources

Vertex Pharmaceuticals · Company filing

Futu · Vertex Pharmaceuticals company profile

Sources checked

For research, not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.